Search results
Showing 631 to 645 of 2581 results for methods
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
In development Reference number: GID-TA11154 Expected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Awaiting development Reference number: GID-TA10638 Expected publication date: TBC
Bortezomib monotherapy for relapsed multiple myeloma (TA129)
Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.
In development Reference number: GID-TA11519 Expected publication date: 12 June 2026
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
IMI and H2020 Grant funded projects with NICE
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]
Awaiting development Reference number: GID-TA11509 Expected publication date: TBC
NICE has developed a Medtech Innovation Briefing (MIB) on the AccuVein AV400 for vein visualisation
Awaiting development Reference number: GID-TA11343 Expected publication date: TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
In development Reference number: GID-TA11410 Expected publication date: TBC
In development Reference number: GID-TA11336 Expected publication date: TBC
In development Reference number: GID-TA11497 Expected publication date: TBC
Artificial intelligence software to help detect and characterise colorectal polyps
In development Reference number: GID-DG10118 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.